NevadaCancer Quality Measures Compared to Achievable Benchmarks

The NHQDR quality measures specific to Cancer are compared to achievable benchmarks, which are derived from the top-performing States. Better performance of a State can mean higher or lower values of a measure, depending on the desired outcome. For example, low values are desirable for measures such as infant mortality, whereas high values are desirable for measures such as preventative screening. The categories of achievement have been standardized across the measure definitions so that:

 
Far away from benchmark - a State's value for a measure has not achieved 50% of the benchmark.
 
Close to benchmark - a State's value for a measure is between 50% and 90% of a benchmark (i.e., worse than the benchmark but has achieved at least half of the benchmark but not as much as 90% of a benchmark).
 
Achieved benchmark or better - a State's value for a measure is no worse than 90% of the benchmark value, the measure has achieved the benchmark. This category also includes the case in which the measure’s value is equal to or better than the benchmark.
Measures That Achieved Benchmark or Better
Measure Estimate Benchmark Distance to Benchmark
Women with clinical Stage I-IIb breast cancer who received axillary node dissection or sentinel lymph node biopsy (SLNB) at the time of surgery (lumpectomy or mastectomy) 95.8 96.8 1.0%
Breast cancer diagnosed at advanced stage (regional, distant stage, or local stage with tumor greater than 2 cm) per 100,000 women age 40 and over 73.6 72.8 1.1%
Patients with colon cancer who received surgical resection of colon cancer that included at least 12 lymph nodes pathologically examined 92.3 95.3 3.1%
Women under age 70 treated for breast cancer with breast-conserving surgery who received radiation therapy to the breast within 1 year of diagnosis 89.1 97.0 8.2%
Colorectal cancer diagnosed at advanced stage (tumors diagnosed at regional or distant stage) per 100,000 population age 50 and over 51.7 47.2 9.6%
Measures That Are Close to Benchmark
Measure Estimate Benchmark Distance to Benchmark
Breast cancer deaths per 100,000 female population per year 21.6 17.8 21.5%
Lung cancer deaths per 100,000 population per year 38.0 27.5 38.4%
Colorectal cancer deaths per 100,000 population per year 16.9 11.5 46.4%
Measures That Are Far From Benchmark
Measure Estimate Benchmark Distance to Benchmark
Cervical cancer diagnosed at advanced stage (all invasive tumors) per 100,000 women age 20 and over 12.0 7.6 58.7%
Measures With No Available Benchmark Information or Supplemental Measures
Measure Estimate Benchmark Distance to Benchmark
Composite measure: Cancer deaths per 100,000 population per year for all cancers 157.3
Tamoxifen or third generation aromatase inhibitor was recommended or administered within 1 year of diagnosis for women with AJCC T1cN0M0 or stage IB to stage III hormone receptor-positive breast cancer 87.8
Composite measure: Adults ages 50-75 who received any type of colorectal cancer screening 62.9
Adults treated at a HRSA supported health centers with appropriate screening for colorectal cancer 29.6